Geneos Wealth Management Inc. Has $2.43 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Geneos Wealth Management Inc. decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 28.5% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 5,014 shares of the medical research company’s stock after selling 2,003 shares during the period. Geneos Wealth Management Inc.’s holdings in Thermo Fisher Scientific were worth $2,432,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of TMO. CBIZ Investment Advisory Services LLC lifted its stake in Thermo Fisher Scientific by 137.5% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 33 shares in the last quarter. Highline Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 126.9% in the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 33 shares during the last quarter. Anderson Financial Strategies LLC bought a new stake in shares of Thermo Fisher Scientific in the first quarter worth $30,000. Capital A Wealth Management LLC grew its position in Thermo Fisher Scientific by 825.0% in the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 66 shares in the last quarter. Finally, DiNuzzo Private Wealth Inc. increased its stake in Thermo Fisher Scientific by 406.7% in the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after buying an additional 61 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $616.97 on Thursday. The company has a market cap of $231.80 billion, a P/E ratio of 35.64, a P/E/G ratio of 4.08 and a beta of 0.91. The firm’s fifty day moving average price is $579.34 and its two-hundred day moving average price is $514.40. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $628.08. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The company had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter last year, the company posted $5.28 EPS. Thermo Fisher Scientific’s quarterly revenue was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a dividend of $0.43 per share. The ex-dividend date is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.94%.

Thermo Fisher Scientific announced that its board has authorized a share repurchase plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s management believes its shares are undervalued.

Wall Street Analysts Forecast Growth

TMO has been the subject of several analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Tuesday, October 14th. Evercore ISI reissued an “outperform” rating and issued a $650.00 price objective on shares of Thermo Fisher Scientific in a report on Monday. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. The Goldman Sachs Group initiated coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, December 9th. They issued a “buy” rating and a $685.00 price target for the company. Finally, UBS Group boosted their price objective on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a research note on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $621.70.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 7,250 shares of the business’s stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $566.10, for a total value of $4,104,225.00. Following the completion of the sale, the chief executive officer owned 113,762 shares of the company’s stock, valued at approximately $64,400,668.20. The trade was a 5.99% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Lisa P. Britt sold 1,058 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $588.26, for a total transaction of $622,379.08. Following the transaction, the vice president directly owned 13,087 shares in the company, valued at approximately $7,698,558.62. This represents a 7.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 149,271 shares of company stock worth $86,507,282 in the last 90 days. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.